Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05244629
Other study ID # 88754
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 2023
Est. completion date August 2029

Study information

Verified date June 2023
Source Rigshospitalet, Denmark
Contact Timothy A Resch, MD, PhD
Phone +45 35 45 79 31
Email timothy.andrew.resch@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic mesenteric ischemia (CMI) is often caused by narrowings in the arteries providing blood to the intestines. Endovascular stent placement is considered the preferred treatment for this condition. Guidelines increasingly support the use of so called covered stents (CS) in stead of bare stents (BMS) for this use but the level of evidence for this is limited. Using CS incur additional costs for healthcare short-term but may prevent recurrence of narrowing and symptoms postoperatively benefitting patients and healthcare. Study Objective: To evaluate the outcomes after stenting of mesenteric arteries using BMS or CS. Study Outcome: Primary stent patency 1 year after placement The trial will also evaluate complications, how often stents need to be reoperated, Quality of Life (QoL) and reasons for subjects death Method: This is a so called prospective, randomized controlled trial comparing CS vs. BMS. This means that one patients have agrred to treatment they will be randomly selected for treatment with either CS or BMS . The stent metal structure is identical in the two implants and the only difference is the graft covering, making this study unique. The study will also collect blood samples for a biobank that will be used to study markers of disease and how these effect treatment outcomes. All patients referred to the Department of Vascular Surgery due to CMI are considered for inclusion if they havechronic symptoms consistent with CMI, significant stenosis or occlusion of the superior mesenteric artery and are > 18 years Subjects not able to provide informed consent or who have non atherosclerotic cause of CMI, signs of acute loss of blood flow to the intestines cannot participate. Previous stent treatment in the superior mesenteric artery, pregnancy, allergies to contrast or stent materials are also reasons for not being included in this trial. Side effects, risks and disadvantages for participants The risk for procedure-related complications is less than 5% and similar in both study groups. Most short-term complications are related to vascular access sites and consist of local bleeding and thrombosis. Other potential complications include impaired renal function due to contrast use, contrast allergy, arterial dissection and death.


Recruitment information / eligibility

Status Recruiting
Enrollment 98
Est. completion date August 2029
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with symptomatic CMI of atherosclerotic or atherothrombotic etiology - Intended endovascular treatment - Symptoms consistent with CMI (pain, weight loss, diarrhea) - Significant ostial stenosis (>50%) of the superior mesenteric artery on CTA - Significant stenosis on angiography (>50% or >15mmHg pressure gradient) - Patients > 18 years Exclusion Criteria: - No informed consent - Non atherosclerotic cause of MI - Acute mesenteric ischemia (AMI) - Signs of acute bowel ischemia, peritonitis, laparotomy, sepsis - Previous stent treatment in the superior mesenteric artery(ies) - Target artery lesions >4cm in length - Unable to cross lesion with guidewire - Non-significant stenosis angiographically - Pregnancy - Allergies to contrast media or stent materials

Study Design


Intervention

Device:
BMS vs. CS
Patients will be randomized to treatment with either BeSmooth (BMS, Bentley Innomed GmBh) or BeGraft (CS, Bentley Innomed Gmbh)

Locations

Country Name City State
Denmark Department of Vascular Surgery, Heart Center, Copenhagen University Hospital - Rigshospitalet København ø

Sponsors (2)

Lead Sponsor Collaborator
Rigshospitalet, Denmark University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with open stents after 12 months No evidence of occlusion, thrombosis or in-stent restenosis more than 30 percent 12 months
Secondary Survival reintervention free and overall survival 5 years
Secondary Quality of life accoring to SF 36 variables SF 36 5 years
See also
  Status Clinical Trial Phase
Completed NCT01205776 - EXCEL Clinical Trial N/A
Completed NCT01231035 - REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary Syndromes (RECLOSE 2 - ACS) N/A
Completed NCT01182428 - XIENCE V: SPIRIT WOMEN Sub-study Phase 4
Completed NCT04580602 - Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects
Completed NCT01205789 - EXCEL Clinical Trial (Universal Registry) N/A
Completed NCT00647504 - Prospective Clinical Observational Registry Including Consecutive Patients With In-stent Restenosis or Stent Thrombosis N/A
Active, not recruiting NCT00905008 - Long-Term Safety of Drug Eluting Stents in the "Real World" (FReIburger STent Registry) N/A
Completed NCT03118895 - Leaders Free III: BioFreedomâ„¢ Clinical Trial N/A
Completed NCT01249027 - XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
Recruiting NCT06075602 - COMPLEX Registry - A Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting With compLEX and Calcified Coronary Artery Disease
Completed NCT03209843 - Post-stenting Assessment of Reendothelialization With OFDI After CTO Procedure (PERFECTO) N/A
Completed NCT01086228 - XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan N/A
Completed NCT00998127 - Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients N/A
Completed NCT00180479 - SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) Phase 3
Recruiting NCT04988685 - SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters
Completed NCT03544294 - veRy Thin Stents for Patients With Left mAIn or bifurcatioN in Real Life: the RAIN a Multicenter Study
Completed NCT04734028 - PTRG-DES Consortium
Completed NCT01894152 - XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study
Completed NCT00496938 - XIENCE V: SPIRIT WOMEN Phase 4
Completed NCT02617290 - Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting Phase 3